Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | OTC | P00480 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 4/20 | 0.39 |
| ▸ | NOS3 | P29474 | 3/20 | 0.39 |
| ▸ | NOS1 | P29475 | 3/20 | 0.39 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL1840912 | 1.00 | PRCP (0.40) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL17113848 | 1.00 | PRCP (0.40) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL20242303 | 1.00 | PRCP (0.40) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL15941091 | 1.00 | PRCP (0.40) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL28914483 | 1.00 | PRCP (0.40) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL17113850 | 1.00 | PRCP (0.40) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL27869599 | 0.99 | PRCP (0.40) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL28855814 | 0.99 | PRCP (0.40) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL27367953 | 0.98 | PRCP (0.39) | PRCPOTCNOS2NOS3NOS1 | |
| Arginine SCHEMBL8582228 | 0.95 | PRCP (0.38) | PRCPOTCNOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092030-A1 | SELF-ASSEMBLING NANOPARTICLES | VACCITECH NORTH AMERICA, INC. (US) | 2024-05-02 | — | — | WO | claimed |
| US-20230147962-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2023-05-11 | — | — | US | claimed |
| EP-3987027-A1 | ENDONUCLEASE-RESISTANT MESSENGER RNA AND USES THEREOF | ModernaTX, Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| US-20210188939-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PROTECTING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2021-06-24 | — | — | US | claimed |
| WO-2020263883-A1 | ENDONUCLEASE-RESISTANT MESSENGER RNA AND USES THEREOF | MODERNATX, INC. (US) | 2020-12-30 | — | — | WO | claimed |
| US-20200308219-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2020-10-01 | — | — | US | claimed |
| US-20200054741-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | AVIDEA TECHNOLOGIES, INC. (US) | 2020-02-20 | — | — | US | claimed |
| EP-3606551-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | Avidea Technologies, Inc. (US) | 2020-02-12 | — | — | EP | claimed |
| US-20190169231-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION | 2019-06-06 | — | — | US | claimed |
| WO-2019079285-A1 | METHODS AND COMPOSITIONS FOR TREATING AND PROTECTING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2019-04-25 | — | — | WO | claimed |
| US-20150203814-A1 | METHODS OF ISOLATING AND CULTURING STEM CELLS | TISSUETECH, INC. (US) | 2015-07-23 | — | — | US | claimed |
| US-20150166624-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH, INC. (US) | 2015-06-18 | — | — | US | claimed |
| EP-2872181-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | Tissuetech, Inc. (US) | 2015-05-20 | — | — | EP | claimed |
| CN-104619352-A | Compositions containing hc-ha/ptx3 complexes and methods of use thereof | TISSUETECH INC | 2015-05-13 | — | — | CN | claimed |
| WO-2014011813-A1 | COMPOSITIONS CONTAINING HC-HA/PTX3 COMPLEXES AND METHODS OF USE THEREOF | TISSUETECH, INC. (US) | 2014-01-16 | — | — | WO | claimed |
| EP-2654899-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS AND COMPOSITIONS AND MATERIALS THEREFOR | Scidec, LLC (US) | 2013-10-30 | — | — | EP | claimed |
| US-20130251684-A1 | METHODS OF ISOLATING AND CULTURING STEM CELLS | TISSUETECH, INC. (US) | 2013-09-26 | — | — | US | claimed |
| WO-2012088133-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS AND COMPOSITIONS AND MATERIALS THEREFOR | DAVIES STEPHEN (US) | 2012-06-28 | — | — | WO | claimed |
| US-20120157976-A1 | METHODS FOR TREATING NEUROLOGICAL CONDITIONS AND COMPOSITIONS AND MATERIALS THEREFOR | SCIDEC THERAPEUTICS, INC. | 2012-06-21 | — | — | US | claimed |
| US-5985273-A | AMINOPEPTIDASE INHIBITORS OR METALLOPEPTIDASE INHIBITORS AND FURTHER COMPRISE A NON-STRONGLY-CHELATING PEPTIDASE INHIBITOR. | REED BENJAMIN J (AU) | 1999-11-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147962-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | FAP, FIBP, FGFR1 | PRCP 92/4885OTC 4386/4885NOS2 4016/4885 |
| US-20200054741-A1 | PEPTIDE-BASED VACCINES, METHODS OF MANUFACTURING, AND USES THEREOF FOR INDUCING AN IMMUNE RESPONSE | MYD88, ICOS, CD4 | PRCP 268/4885OTC 4422/4885NOS2 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.